var data={"title":"Rocuronium: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rocuronium: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6922?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rocuronium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rocuronium: Patient drug information&quot;</a> and <a href=\"topic.htm?path=rocuronium-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rocuronium: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219069\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zemuron [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219070\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rocuronium Bromide Injection;</li>\n      <li>Zemuron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219099\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Neuromuscular Blocker Agent, Nondepolarizing</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219073\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Rapid sequence intubation:</b> IV: 0.6 to 1.2 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Obesity: In adult patients with morbid obesity (BMI &gt;40 kg/m<sup>2</sup>), the use of 1.2 mg/kg using ideal body weight (IBW) provided a short onset of action and excellent or good intubating conditions at 60 seconds in one study (Gaszynski, 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Tracheal intubation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Initial:</i> 0.45 to 0.6 mg/kg; administration of 0.3 mg/kg may also provide optimal conditions for tracheal intubation (Barclay, 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Obesity: May use ideal body weight (IBW) for morbidly obese (BMI &gt;40 kg/m<sup>2</sup>) adult patients (Leykin, 2004); onset time may be slightly delayed using IBW. The manufacturer recommends dosing based on actual body weight in all obese patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Maintenance for continued surgical relaxation:</i> 0.1 to 0.2 mg/kg; repeat as needed <b>or</b> a continuous infusion of 10 to 12 <b>mcg</b>/kg/<b>minute</b> (0.6 to 0.72 <b>mg</b>/kg/<b>hour</b>) only after recovery of neuromuscular function is evident; infusion rates have ranged from 4 to 16 <b>mcg</b>/kg/<b>minute</b> (0.24 to 0.96 <b>mg</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <b>Note:</b> Inhaled anesthetic agents prolong the duration of action of rocuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preinduction defasciculation (off-label use):</b> IV: 0.03 to 0.06 mg/kg given 1.5 to 3 minutes before administration of succinylcholine (Harvey, 1998; Martin, 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>ICU paralysis (eg, facilitate mechanical ventilation) in adequately sedated patients (off-label use):</b> Initial bolus dose: 0.6 to 1 mg/kg, then a continuous IV infusion of 8 to 12 <b>mcg</b>/kg/<b>minute</b> (0.48 to 0.72 <b>mg</b>/kg/<b>hour</b>); monitor depth of blockade every 2 to 3 hours initially until stable dose, then every 8 to 12 hours; adjust rate of administration by 10% increments according to peripheral nerve stimulation response or desired clinical response (Greenberg, 2013; Murray, 2002; Rudis, 1996; Sparr, 1997; Warr, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <b>Note:</b> When possible, minimize depth and duration of paralysis. Stopping the infusion for some time until forced to restart based on patient condition is recommended to reduce post-paralytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (Murray, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>Intermittent dosing</i> has also been described with an initial loading dose of 50 mg followed by 25 mg given when peripheral nerve stimulation returns (Sparr, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219085\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=rocuronium-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rocuronium: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neonates, Infants, Children, and Adolescents: <b>Note:</b> In general, onset is shortened and duration is prolonged as dose increases. Duration is shortest in children &gt;2 to &le;11 years and longest in neonates and infants. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tracheal intubation:</b> IV: 0.45 mg/kg or 0.6 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance for continued surgical relaxation:</i> IV: 0.075 to 0.15 mg/kg; redosing interval is guided by monitoring with a peripheral nerve stimulator <b>or</b> 7 to 12 <b>mcg</b>/kg/<b>minute</b> (0.42 to 0.72 <b>mg</b>/kg/<b>hour</b>) as a continuous infusion; use lower end of the continuous infusion dosing range for neonates and the upper end for children &gt;2 to &le;11 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Rapid sequence intubation (off-label use): </b>IV: 0.9 mg/kg or 1.2 mg/kg. Not recommended, per the manufacturer, for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication in children &gt;1 year (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219074\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7282609\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Duration of neuromuscular blockade may vary in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7282610\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330600\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219051\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemuron: 50 mg/5 mL (5 mL [DSC]); 100 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219054\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV only; may be administered as a bolus injection (undiluted) or via a continuous infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219052\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neuromuscular blockade:</b> As an adjunct to general anesthesia to facilitate rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27628499\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intensive care unit paralysis:; Preinduction defasciculation:</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219106\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zemuron may be confused with Remeron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219043\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Increased peripheral vascular resistance (abdominal aortic surgery: 24%, frequency not defined during other procedures), tachycardia (&le;5%; incidence greater in children), hypertension, transient hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, asthma, cardiac arrhythmia, ECG abnormality, edema at insertion site, hiccups, nausea, pruritus, skin rash, vomiting </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219057\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to rocuronium, other neuromuscular-blocking agents, or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219041\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use is contraindicated in patients with previous anaphylactic reactions to other neuromuscular blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged paralysis: Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Patients should be adequately recovered prior to extubation. Other factors associated with prolonged recovery should be considered (eg, corticosteroid use, patient condition).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure); onset of action may be delayed and duration of action may be prolonged. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions that may <i>antagonize</i> neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Murray, 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions that may <i>potentiate</i> neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), cachexia, neuromuscular diseases, metabolic acidosis, metabolic alkalosis,  respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary hypertension:  Use with caution in patients with pulmonary hypertension; use may increase pulmonary vascular resistance worsening symptoms of right heart failure. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Valvular heart disease: Use with caution in patients with valvular heart disease; use may increase pulmonary vascular resistance.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&bull; Corticosteroids: In addition to prolonging recovery from neuromuscular blockade, concomitant use with corticosteroids has been associated with development of acute quadriplegic myopathy syndrome (AQMS). Current guidelines recommend neuromuscular blockers be discontinued as soon as possible in patients receiving corticosteroids or interrupted daily until necessary to restart them based on clinical condition (Murray, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&bull; High potential for interactions: Numerous drugs either <i>antagonize</i> (eg, acetylcholinesterase inhibitors) or <i>potentiate</i> (eg, calcium channel blockers, certain antimicrobials, inhalation anesthetics, lithium, magnesium salts, procainamide, and quinidine) the effects of neuromuscular blockade; use with caution in patients receiving these agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Not recommended by the manufacturer for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.  Rocuronium does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation. In patients requiring long-term administration in the ICU, tolerance to rocuronium may develop; use of a peripheral nerve stimulator to monitor drug effects is strongly recommended. Additional doses of rocuronium or any other neuromuscular-blocking agent should be avoided unless definite excessive response to nerve stimulation is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: If extravasation occurs, local irritation may ensue; discontinue administration immediately and restart in another vein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300012\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219045\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9872&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the therapeutic effect of Rocuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219060\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg  (Abouleish, 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15683458\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to rocuronium use and breast-feeding has not been located. If present in breast milk, oral absorption by a nursing infant would be expected to be minimal (Lee, 1993).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219049\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Peripheral nerve stimulator measuring twitch response, heart rate, blood pressure, assisted ventilation status</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219040\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219056\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;3 months and Children: 30 seconds to 1 minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Good intubation conditions within 1 to 2 minutes (depending on dose administered); maximum neuromuscular blockade within 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 3 to 12 months: 40 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 1 to 12 years: 26 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~30 minutes (with standard doses, increases with higher doses and inhalational anesthetic agents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 0.21 to 0.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.22 to 0.26 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic dysfunction: 0.53 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal dysfunction: 0.34 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic; 17-desacetylrocuronium (5% to 10% activity of parent drug) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alpha elimination: 1 to 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Beta elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 3 to 12 months: 1.3 &plusmn; 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to &lt;3 years: 1.1 &plusmn; 0.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 3 to &lt;8 years: 0.8 &plusmn; 0.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 1.4 to 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hepatic impairment: 4.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal impairment: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (31%); urine (26%) (Proost 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Pediatric patients: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 3 to &lt;12 months: 0.35 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to &lt;3 years: 0.32 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 3 to &lt;8 years: 0.44 L/kg/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323798\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rocuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $4.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $8.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Rocuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $9.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219061\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Curionialis (MX);</li>\n      <li>Desproxyl (MX);</li>\n      <li>Eslax (JP);</li>\n      <li>Esmeron (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UA, VE, VN, YE);</li>\n      <li>Kabiroc (ID);</li>\n      <li>Rocum (ID);</li>\n      <li>Rocumeron (KR);</li>\n      <li>Rocur (UY);</li>\n      <li>Rocuron (BD);</li>\n      <li>Rocuronio (CO);</li>\n      <li>Romeron (KR);</li>\n      <li>Zemuron (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abouleish E, Abboud T, Lechevalier T, et al, &quot;Rocuronium (Org 9426) for Caesarean Section,&quot; <i>Br J Anaesth</i>, 1994, 73(3):336-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/7946860/pubmed\" target=\"_blank\" id=\"7946860\">7946860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barclay K, Eggers K, and Asai T, &ldquo;Low-Dose Rocuronium Improves Conditions for Tracheal Intubation After Induction of Anaesthesia With Propofol and Alfentanil,&rdquo; <i>Br J Anaesth</i>, 1997, 78(1):92-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9059214/pubmed\" target=\"_blank\" id=\"9059214\">9059214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartkowski RR, Witkowski TA, Azad S, et al, &ldquo;Rocuronium Onset of Action: A Comparison With Atracurium and Vecuronium,&rdquo; <i>Anesth Analg</i>, 1993, 77(3):574-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8103649/pubmed\" target=\"_blank\" id=\"8103649\">8103649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng CA, Aun CST, and Gin T, &ldquo;Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children,&rdquo; <i>Paediatr Anaesth</i>, 2002, 12(2):140-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11882225/pubmed\" target=\"_blank\" id=\"11882225\">11882225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheymol G, &ldquo;Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy,&rdquo; <i>Clin Pharmacokinet</i>, 2000, 39(3):215-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11020136/pubmed\" target=\"_blank\" id=\"11020136\">11020136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL, &ldquo;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&rdquo; <i>Intensive Care Med</i>, 2004, 30(1):18-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/14625670/pubmed\" target=\"_blank\" id=\"14625670\">14625670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs-Buder T and Tassonyi E, &ldquo;Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children,&rdquo; <i>Br J Anaesth</i>, 1996, 77(3):335-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8949805/pubmed\" target=\"_blank\" id=\"8949805\">8949805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaszynski TM, Szewczyk T. &ldquo;Rocuronium for Rapid Sequence Induction in Morbidly Obese Patients: A Prospective Study for Evaluation of Intubation Conditions After Administration 1.2 mg kg<sup>-1 </sup>Ideal Body Weight of Rocuronium,&rdquo; <i>Eur J Anaesthesiol</i>, 2011, 28(8):609-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/21562423/pubmed\" target=\"_blank\" id=\"21562423\">21562423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH and Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus.<i>Br J Anaesth</i>. 2009, 102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9728861\"></a>Harvey SC, Roland P, Bailey MK, et al, &quot;A Randomized, Double-Blind Comparison of Rocuronium, d-Tubocurarine, and 'Mini-Dose' Succinylcholine for Preventing Succinylcholine-Induced Muscle Fasciculations,&quot; <i>Anesth Analg</i>, 1998, 87(3):719-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9728861/pubmed\" target=\"_blank\" id=\"9728861\">9728861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8557012\"></a>Khuenl-Brady KS, Sparr H, Puhringer F, et al, &ldquo;Rocuronium Bromide in the ICU: Dose Finding and Pharmacokinetics,&rdquo; <i>Eur J Anaesthesiol Suppl</i>, 1995, 11:79-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8557012/pubmed\" target=\"_blank\" id=\"8557012\">8557012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JJ and Rubin AP, &quot;Breast Feeding and Anaesthesia,&quot; <i>Anaesthesia</i>, 1993, 48(7):616-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8346780/pubmed\" target=\"_blank\" id=\"8346780\">8346780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leykin Y, Pellis T, Lucca M, et al, &ldquo;The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients,&rdquo; <i>Anesth Analg</i>, 2004, 99(4):1086-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/15385355/pubmed\" target=\"_blank\" id=\"15385355\">15385355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9669004\"></a>Martin R, Carrier J, Pirlet M, et al, &quot;Rocuronium is the Best Non-Depolarizing Relaxant to Prevent Succinylcholine Fasciculations and Myalgia,&quot; <i>Can J Anaesth</i>, 1998, 45(6):521-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9669004/pubmed\" target=\"_blank\" id=\"9669004\">9669004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazurek AJ, Rae B, Hann S, et al, &ldquo;Rocuronium versus Succinylcholine: Are They Equally Effective During Rapid-Sequence Induction of Anesthesia?&rdquo; <i>Anesth Analg</i>, 1998, 87:1259-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9842809/pubmed\" target=\"_blank\" id=\"9842809\">9842809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meretoja OA, Taivainen T, Jalkanen L, et al, &ldquo;Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,&rdquo; <i>Br J Anaesth</i>, 1994, 73(5):605-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/7826787/pubmed\" target=\"_blank\" id=\"7826787\">7826787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo; <i>Crit Care Med</i>, 2002, 30(1):142-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11902255/pubmed\" target=\"_blank\" id=\"11902255\">11902255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. <i>Anesthesiology</i>. 2002; 96(1): 202-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11753022/pubmed\" target=\"_blank\" id=\"11753022\">11753022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naguib M, Samarkandi AH, Ammar A, et al, &ldquo;Comparison of Suxamethonium and Different Combinations of Rocuronium and Mivacurium for Rapid Tracheal Intubation in Children,&rdquo;<i>Br J Anaesth</i>, 1997, 79(4):450-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9389261/pubmed\" target=\"_blank\" id=\"9389261\">9389261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. <i>Br J Anaesth</i>. 2000 Nov;85(5):717-723.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11094587/pubmed\" target=\"_blank\" id=\"11094587\">11094587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puhringer FK, Khuenl-Brady KS, and Mitterschiffthaler G, &ldquo;Rocuronium Bromide: Time-Course of Action in Underweight, Normal Weight, Overweight and Obese Patients,&rdquo; <i>Eur J Anaesthesiol Suppl</i>, 1995, 11:107-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8556996/pubmed\" target=\"_blank\" id=\"8556996\">8556996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocuronium bromide [prescribing information]. Windsor, NJ: AuroMedics Pharma LLC; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudis MI, Guslits BG, and Zarowitz BJ, &ldquo;Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(2):165-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8835051/pubmed\" target=\"_blank\" id=\"8835051\">8835051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9135303\"></a>Sparr HJ, Wierda JM, Proost JH, et al, &ldquo;Pharmacodynamics and Pharmacokinetics of Rocuronium in Intensive Care Patients,&rdquo; <i>Br J Anaesth</i>, 1997, 78(3):267-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9135303/pubmed\" target=\"_blank\" id=\"9135303\">9135303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warr J, Thiboutot Z, Rose L, et al, &ldquo;Current Therapeutic Uses, Pharmacology, and Clinical Considerations of Neuromuscular Blocking Agents for Critically Ill Adults,&rdquo; <i>Ann Pharmacother</i>, 2011, 45(9):1116-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/21828347/pubmed\" target=\"_blank\" id=\"21828347\">21828347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemuron (rocuronium) [prescribing information]. Bloomington, IN: Organon; January 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9872 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F219069\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F219070\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F219099\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F219073\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F219085\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F219074\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7282609\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7282610\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330600\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F219051\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F219037\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F219054\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F219052\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27628499\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F219106\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F219043\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F219057\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F219041\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300012\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F219045\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F219047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F219060\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15683458\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F219049\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219040\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F219056\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323798\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F219061\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9872|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rocuronium-patient-drug-information\" class=\"drug drug_patient\">Rocuronium: Patient drug information</a></li><li><a href=\"topic.htm?path=rocuronium-pediatric-drug-information\" class=\"drug drug_pediatric\">Rocuronium: Pediatric drug information</a></li></ul></div></div>","javascript":null}